Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine.

Related Articles

Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine.

NPJ Vaccines. 2017;2:32

Authors: Wei H, Chen Z, Elson A, Li Z, Abraham M, Phan S, Kristhnamurthy S, McCray PB, Andrews S, Stice S, Sakamoto K, Jones C, Tompkins SM, He B

Abstract
Delivery of a gene of interest to target cells is highly desirable for translational medicine, such as gene therapy, regenerative medicine, vaccine development, and studies of gene function. Parainfluenza virus 5 (PIV5), a paramyxovirus with a negative-sense RNA genome, normally infects cells without causing obvious cytopathic effect, and it can infect many cell types. To exploit these features of PIV5, we established a system generating self-amplifying, virus-like particles (AVLP). Using enhanced green fluorescent protein (EGFP) as a reporter, AVLP encoding EGFP (AVLP-EGFP) successfully delivered and expressed the EGFP gene in primary human cells, including stem cells, airway epithelial cells, monocytes, and T cells. To demonstrate the application of this system for vaccine development, we generated AVLPs to express the HA and M1 antigens from the influenza A virus strain H5N1 (AVLP-H5 and AVLP-M1H5). Immunization of mice with AVLP-H5 and AVLP-M1H5 generated robust antibody and cellular immune responses. Vaccination with a single dose of AVLP-H5 and M1H5 completely protected mice against lethal H5N1 challenge, suggesting that the AVLP-based system is a promising platform for delivery of desirable genes.

PMID: 29263887 [PubMed]

http://ift.tt/2pf61yE